CN110585226B - 金线莲苷在制备改善认知功能障碍的药物中的用途 - Google Patents
金线莲苷在制备改善认知功能障碍的药物中的用途 Download PDFInfo
- Publication number
- CN110585226B CN110585226B CN201911114215.5A CN201911114215A CN110585226B CN 110585226 B CN110585226 B CN 110585226B CN 201911114215 A CN201911114215 A CN 201911114215A CN 110585226 B CN110585226 B CN 110585226B
- Authority
- CN
- China
- Prior art keywords
- cognitive dysfunction
- group
- glycoside
- anoectochilus formosanus
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000010877 cognitive disease Diseases 0.000 title claims abstract description 51
- 229930182470 glycoside Natural products 0.000 title claims abstract description 43
- 150000002338 glycosides Chemical class 0.000 title claims abstract description 43
- 239000003814 drug Substances 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims description 3
- 241000719836 Anoectochilus formosanus Species 0.000 title abstract description 31
- 150000003839 salts Chemical class 0.000 claims abstract description 22
- 208000024714 major depressive disease Diseases 0.000 claims description 21
- 241000934230 Anoectochilus roxburghii Species 0.000 claims description 15
- 201000004810 Vascular dementia Diseases 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000006186 oral dosage form Substances 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 20
- 241000699670 Mus sp. Species 0.000 description 24
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 208000024827 Alzheimer disease Diseases 0.000 description 15
- 230000000694 effects Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 208000006011 Stroke Diseases 0.000 description 9
- 230000003920 cognitive function Effects 0.000 description 9
- 208000028867 ischemia Diseases 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 208000018737 Parkinson disease Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- MQEPWBMWFIVRPS-ZGSHZZHUSA-N (3R)-5-Oxotetrahydro-3-furanyl beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1CC(=O)OC1 MQEPWBMWFIVRPS-ZGSHZZHUSA-N 0.000 description 4
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 4
- 208000028698 Cognitive impairment Diseases 0.000 description 4
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 4
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 125000003563 glycoside group Chemical group 0.000 description 4
- MQEPWBMWFIVRPS-UHFFFAOYSA-N goodyeroside A Natural products OC1C(O)C(O)C(CO)OC1OC1CC(=O)OC1 MQEPWBMWFIVRPS-UHFFFAOYSA-N 0.000 description 4
- 230000007087 memory ability Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000010410 reperfusion Effects 0.000 description 4
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 4
- 229960002646 scopolamine Drugs 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 210000001168 carotid artery common Anatomy 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 241000719837 Anoectochilus Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 201000007201 aphasia Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000000269 carotid artery external Anatomy 0.000 description 2
- 210000004004 carotid artery internal Anatomy 0.000 description 2
- 210000002932 cholinergic neuron Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000003930 cognitive ability Effects 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000007074 memory dysfunction Effects 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 1
- 208000017164 Chronobiology disease Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 1
- 108091093073 MiR-134 Proteins 0.000 description 1
- RFPZGZUMXXMVEL-UBSYNHCDSA-N Nelumboside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)[C@H](O)[C@H]1O RFPZGZUMXXMVEL-UBSYNHCDSA-N 0.000 description 1
- RFPZGZUMXXMVEL-UHFFFAOYSA-N Nelumboside Natural products OC1C(O)C(O)C(CO)OC1OC1C(C(O)=O)OC(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)C(O)C1O RFPZGZUMXXMVEL-UHFFFAOYSA-N 0.000 description 1
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 102000000344 Sirtuin 1 Human genes 0.000 description 1
- 108010041191 Sirtuin 1 Proteins 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- -1 hydroxyl hydrogen Chemical compound 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960004499 scopolamine hydrobromide Drugs 0.000 description 1
- WTGQALLALWYDJH-MOUKNHLCSA-N scopolamine hydrobromide (anhydrous) Chemical compound Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 WTGQALLALWYDJH-MOUKNHLCSA-N 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911114215.5A CN110585226B (zh) | 2019-11-14 | 2019-11-14 | 金线莲苷在制备改善认知功能障碍的药物中的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911114215.5A CN110585226B (zh) | 2019-11-14 | 2019-11-14 | 金线莲苷在制备改善认知功能障碍的药物中的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110585226A CN110585226A (zh) | 2019-12-20 |
CN110585226B true CN110585226B (zh) | 2020-08-11 |
Family
ID=68852417
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911114215.5A Active CN110585226B (zh) | 2019-11-14 | 2019-11-14 | 金线莲苷在制备改善认知功能障碍的药物中的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110585226B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115737663A (zh) * | 2022-12-12 | 2023-03-07 | 武汉市精神卫生中心 | 金线莲苷在防治抑郁症中的应用 |
CN116334216B (zh) * | 2023-05-29 | 2023-09-15 | 中国人民解放军军事科学院军事医学研究院 | Cldn5基因在调控认知障碍中的功能及应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1895966A4 (en) * | 2005-04-26 | 2010-01-20 | Ko Boong Kyung | PROCESS FOR EXTRACTION OF GINSENGNOSID RG2M; PHARMACEUTICAL COMPOSITION WITH GINSENGNOSID RG2, AND ITS USES |
TWI369207B (en) * | 2007-03-29 | 2012-08-01 | Univ China Medical | Aqueous extracts of anoectochilus spp. and uses of the same |
CN101411716B (zh) * | 2008-07-08 | 2011-05-04 | 中国人民解放军第二军医大学 | 虎杖苷用于制备抗痴呆产品的用途 |
CN101496865B (zh) * | 2009-03-19 | 2011-06-15 | 杨颖� | 一种治疗抑郁症、焦虑症的中药制剂及其制备方法 |
CN109381472A (zh) * | 2017-08-02 | 2019-02-26 | 华中科技大学 | 一种糖苷类化合物在制备用于治疗肝纤维化药物中的应用 |
CN108721384A (zh) * | 2018-07-24 | 2018-11-02 | 启东创潞新材料有限公司 | 一种金线草抗炎作用提取物的制备方法 |
-
2019
- 2019-11-14 CN CN201911114215.5A patent/CN110585226B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN110585226A (zh) | 2019-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110585226B (zh) | 金线莲苷在制备改善认知功能障碍的药物中的用途 | |
US10660872B2 (en) | Methods for treatment of cognitive decline | |
Wyatt et al. | Longitudinal studies of the effect of monoamine oxidase inhibitors on sleep in man | |
KR20140072819A (ko) | 포스포디에스테라제 타입 5 저해제를 포함하는 신경세포의 아폽토시스 억제용 조성물 | |
CN107951869A (zh) | 含有大麻二酚的药物制剂及其应用 | |
MX2012001814A (es) | Uso de 4-aminopiridina para mejorar la discapacidad neuro - cognoscitiva y/o neuro - psiquiatrica en pacientes con condiciones desmielizantes y otras condiciones del sistema nervioso. | |
Sachs et al. | BLOOD SUGAR STUDIES IN EXPERIMENTAL PITUITARY AND HYPOTHALAMIC LESIONS: WITH A REVIEW OF LITERATURE | |
EP1383495A1 (en) | Duloxetine for treatment of hot flashes | |
CN108310234A (zh) | 一种治疗认知功能障碍的药物组合物及其制备方法、制剂与应用 | |
JPS5910585A (ja) | スピロスクシンイミド誘導体のアルツハイマ−型痴「ほう」の治療における使用 | |
CN101108185A (zh) | 用于治疗、改变和控制疼痛的包含免疫调节化合物的组合物 | |
CN112569237B (zh) | 伊马替尼及其衍生物与尼古丁或其类似物联用或复方在防治尼古丁成瘾与复吸中的应用 | |
CN107613966A (zh) | 阿片类物质和n‑酰基乙醇胺的组合 | |
Kelly et al. | Nutritional management of the patient with a neurologic disorder | |
CN115595315A (zh) | 核糖核酸酶i在抑制疼痛的药物中的新用途 | |
Hinsie | The treatment of schizophrenia: A survey of the literature | |
JP4135977B2 (ja) | β−受容体遮断薬とオピオイドとの新規な組合せ物 | |
Fraser et al. | Chlorpromazine and Reserpine:(A) Effects of Each and of Combinations of Each with Morphine (B) Failure of Each in Treatment of Abstinence from Morphine | |
Kalaivani | Methamphetamine substance abuse and Dental Considerations: a modern era crisis | |
CN112972462B (zh) | 帕比司他在制备预防、缓解和/或治疗多发性硬化症药物中的应用 | |
CN107281183B (zh) | 一种镇痛药物组合物 | |
Fager | Effectiveness of stereoencephalotomy in treatment of Parkinson's disease | |
HORTON et al. | Use of antihistamine drugs in the treatment for trigeminal neuralgia | |
JPH07503972A (ja) | 外傷後のストレスの治療用薬剤としてのブロファロミン | |
Hsu et al. | M201 should FENO be used as a biomarker to measure response to benralizumab? |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210927 Address after: 351154 No. 119, Xiguo, Shanting village, Shanting Town, North Bank Economic Development Zone, Meizhou Bay, Putian City, Fujian Province Patentee after: Fujian Jinlan Houpu Biotechnology Co.,Ltd. Address before: 330004 room 626, building 3, industrial park beside Meiling National Forest Park, Wanli District, Nanchang City, Jiangxi Province Patentee before: Jiangxi Houpu Guanzhong Technology Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240317 Address after: 211106, 21st Floor, Building A, Mingjia Technology Building, No. 99 Shengli Road, Jiangning Development Zone, Jiangning District, Nanjing City, Jiangsu Province Patentee after: NANJING ANGKELI MEDICINE TECHNOLOGY INNOVATION RESEARCH INSTITUTE Co.,Ltd. Country or region after: China Address before: 351154 No. 119, Xiguo, Shanting village, Shanting Town, North Bank Economic Development Zone, Meizhou Bay, Putian City, Fujian Province Patentee before: Fujian Jinlan Houpu Biotechnology Co.,Ltd. Country or region before: China |
|
TR01 | Transfer of patent right |